Accommodations for progressive functional impairment due to Duchenne muscular dystrophy (DMD) incur substantial costs for households in the US, according to a survey of US-based family-member ...

(RTTNews) - Precision BioSciences, Inc. (DTIL) announced Wednesday that the U.S. Food and Drug Administration or FDA has granted Rare Pediatric Disease Designation for PBGENE-DMD, the company's ...

With this designation, Precision may be eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD. The Priority Review Voucher program is designed to incentivize drug ...

DMD Ventures seeks to invalidate a recent foreclosure action against a Fort Lauderdale multifamily development site.

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second ...

Serepta and global partner Roche have suspended the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) in non-ambulatory patients ...

RegenXBio has share | RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that its pivotal dose improves functional outcomes in ...

DMD Diamond (DMD) is a community-run, layer-1 blockchain project that offers several features designed to provide developers with a secure, fully decentralized, and sustainable platform.

The inaugural UNO Social Club will have multicolored UNO decor, and other amenities, and will be located in one of the kidadult capitals of the world, Las Vegas.

In order to accelerate development of PBGENE-DMD and maintain operational capability to pursue PBGENE-HBV and PBGENE-DMD through Phase 1 clinical results, Precision plans to pause development of ...

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.